Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Bupivacaine for Thoracic Paravertebral Block in VATS
ChiCTR2400091217Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of bupivacaine in postoperative pain (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Total opioid consumption within 72 hours after surgery, Maximum NRS pain score 24 hours after surgery and 4 more. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2400091217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091217.